Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin

Cancer

Volumn 103, Issue 12, 2005, Pages 2629-2635

  Chamilos, Georgios ^a,b   Bamias, Aristotle ^a   Efstathiou, Eleni ^a   Zorzou, Pagona M ^a   Kastritis, Efstathios ^a   Kostis, Evagelos ^a   Papadimitriou, Christos ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Moxifloxacin; Neutropenic fever; Outpatient

Indexed keywords

MOXIFLOXACIN;

ADULT; ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NAUSEA; NEUTROPHIL; OUTPATIENT; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTINEOPLASTIC AGENTS; AZA COMPOUNDS; FEMALE; FEVER; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; QUINOLINES; RISK ASSESSMENT; SAFETY; TREATMENT OUTCOME;

EID: 20444400553     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21089     Document Type: Article

References (26)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64: 328-340.
2. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.
3. Rubin M, Hathorn JW, Pizzo PA. Controversies in the management of febrile neutropenic cancer patients. Cancer Invest. 1988;6:167-184.
4. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med. 1988;148:2561-2568.
5. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. 1992;10:316-322.
6. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18: 3038-3051.
7. Kern WV, Cometta A, De Block R, Langenaeken J, Paesmans, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1999;314:312-318.
8. Freifeld A, Marchigiani D, Walsh T, et al. A double blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med. 1999;341:305-311.
9. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol. 1994;12:107-114.
10. Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer. 1993;71:3640-3646.
11. Malik IA, Khan WA, Karim M, Aziz Z, Khan MA. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med. 1995;98:224-231.
12. Innes HE, Smith DB, O'Reilly SM, Clark PI, Kelly V, Marshall E. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomized controlled single centre study. Br J Cancer. 2003;89:43-49.
13. Finberg RW, Talcott JA. Fever and neutropenia-how to use a new treatment strategy. N Engl J Med. 1999;341:362-363.
14. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis. 1999;29:490-494.
15. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case control study of predisposing factors. Clin Infect Dis. 1992;14:1201-1207.
16. Picazo JJ. Management of febrile neutropenic patient: a consensus conference. Clin Infect Dis. 2004;39:S1-S6.
17. Balfour JA, Wiseman LR. Moxifloxacin. Drugs. 1999;57:363-373.
18. Aktas Z, Gonullu N, Salcioglu M, Bal C, Ang O. Moxifloxacin activity against clinical isolates compared with the activity of ciprofloxacin. Int J Antimicrob Agents. 2002;20:196-200.
19. Rolston KV, Frisbee-Hume S, LeBlanc B, Streeter H, Ho DH. In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients. Diagn Microbiol Infect Dis. 2003;47:441-449.
20. Papadimitris C, Dimopoulos MA, Kostis E, et al. Outpatient treatment of neutropenic fever with oral antibiotics and granulocyte colony-stimulating factor. Oncology. 1999;57: 127-130.
21. Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer. 1999;86:126-134.
22. Uys A, Rapoport BL, Anderson R. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer. 2004;12:555-560.
23. Mastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis. 2004;39:S32-S37.
24. Link H, Bohme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever. Ann Hematol. 2003;82 S-2:105-117.
25. Weiss K, Restieri C, De Carolis E, Laverdiere M, Guay H. Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother. 2000;45:363-365.
26. Pong A, Thomson KS, Moland ES, Chartrad SA, Sanders CC. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin. J Antimicrob Chemother. 1999;44:621-627.